34º Congresso Mineiro de Cardiologia
Acesse o site do congresso
1º Dia - 7/10/25
2º Dia - 7/11/25
3º Dia - 7/12/25

MASLD – é um marcador cardiovascular independente? Voltar

Humberto Oliva Galizzi

Simpósio Conjunto SMC e DEIC (Cardiomiopatias) - Marcelo Imbroinisi Bittencourt e Estevão Lanna Figueiredo

Artigo Autor(es) Referência
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach. Chew Nicholas W S, Mehta Anurag, Goh Rachel Sze Jen, Zhang Audrey, Chen Yiming, Chong Bryan, Chew Han Shi Jocelyn, Shabbir Asim, Brown Adrian, Dimitriadis Georgios K, Huang Daniel Q, Foo Roger, le Roux Carel W, Figtree Gemma A, Fudim Marat, Pandey Ambarish, Mamas Mamas A, Hausenloy Derek J, Richards A Mark, Nicholls Stephen J, Chan Mark Y, Muthiah Mark D, Sanyal Arun, Sperling Laurence S Circulation. 2025 Jan; 151(Jan):98-119. doi: 10.1161/CIRCULATIONAHA.124.070535. pii: .
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress. Minetti Erika T, Hamburg Naomi M, Matsui Reiko Frontiers in cardiovascular medicine. 2024 ; 11():1469492. doi: 10.3389/fcvm.2024.1469492. pii: 1469492.
Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality. Kim Jung-Hwan, Lee Yaeji, Nam Chung-Mo, Kwon Yu-Jin, Lee Ji-Won Nutrition, metabolism, and cardiovascular diseases : NMCD. 2025 Jun; 35(Jun):103965. doi: 10.1016/j.numecd.2025.103965. pii: S0939-4753(25)00119-X.
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Targher Giovanni, Byrne Christopher D, Tilg Herbert Gut. 2024 Mar; 73(Mar):691-702. doi: 10.1136/gutjnl-2023-330595. pii: .
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease. Katsiki Niki, Kolovou Genovefa, Vrablik Michal Current cardiology reports. 2025 Jan; 27(Jan):19. doi: 10.1007/s11886-024-02181-9. pii: .
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Chan Wah-Kheong, Chuah Kee-Huat, Rajaram Ruveena Bhavani, Lim Lee-Ling, Ratnasingam Jeyakantha, Vethakkan Shireene Ratna Journal of obesity & metabolic syndrome. 2023 Sep; 32(Sep):197-213. doi: 10.7570/jomes23052. pii: .
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Factor: Focus on Atrial Fibrillation. Awashra Ameer, Nouri Ahmad, Hamdan Ahmad, Said Hanin, Rajab Islam, Hussein Abdallah, Abu Rmilah Anan Cardiology in review. 2025 Apr; doi: 10.1097/CRD.0000000000000932. pii: .
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk. Ionescu Vlad Alexandru, Gheorghe Gina, Bacalbasa Nicolae, Diaconu Camelia Cristina Biomolecules. 2025 Jan; 15(Jan):doi: 10.3390/biom15020163. pii: 163.
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Zheng Haixiang, Sechi Leonardo Antonio, Navarese Eliano Pio, Casu Gavino, Vidili Gianpaolo Cardiovascular diabetology. 2024 Sep; 23(Sep):346. doi: 10.1186/s12933-024-02434-5. pii: 346.
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Lee Hyeok-Hee, Lee Han Ah, Kim Eun-Jin, Kim Hwi Young, Kim Hyeon Chang, Ahn Sang Hoon, Lee Hokyou, Kim Seung Up Gut. 2024 Feb; 73(Feb):533-540. doi: 10.1136/gutjnl-2023-331003. pii: .
Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system. Manolis Antonis A, Manolis Theodora A, Vouliotis Apostolos, Manolis Antonis S Trends in cardiovascular medicine. 2025 May; 35(May):258-265. doi: 10.1016/j.tcm.2025.01.001. pii: S1050-1738(25)00006-4.
Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Platek Anna E, Szymanska Anna Clinical and experimental hepatology. 2023 Sep; 9(Sep):187-192. doi: 10.5114/ceh.2023.130744. pii: .
Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults. Chung Goh Eun, Yu Su Jong, Yoo Jeong-Ju, Cho Yuri, Lee Kyu-Na, Shin Dong Wook, Kim Yoon Jun, Yoon Jung-Hwan, Han Kyungdo, Cho Eun Ju Scientific reports. 2025 Feb; 15(Feb):5777. doi: 10.1038/s41598-025-89293-6. pii: 5777.
Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. Boccatonda Andrea, Del Cane Lorenza, Marola Lara, D'Ardes Damiano, Lessiani Gianfranco, di Gregorio Nicoletta, Ferri Claudio, Cipollone Francesco, Serra Carla, Santilli Francesca, Piscaglia Fabio Life (Basel, Switzerland). 2024 Apr; 14(Apr):doi: 10.3390/life14040473. pii: 473.
Role of MASLD in CVD: A review of emerging treatment options. Mollace Rocco, Longo Susanna, Nardin Matteo, Tavernese Annamaria, Musolino Vincenzo, Cardamone Antonio, Federici Massimo Diabetes research and clinical practice. 2024 Nov; 217(Nov):111891. doi: 10.1016/j.diabres.2024.111891. pii: S0168-8227(24)00801-5.
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. Michalopoulou Eleni, Thymis John, Lampsas Stamatios, Pavlidis George, Katogiannis Konstantinos, Vlachomitros Dimitrios, Katsanaki Eleni, Kostelli Gavriella, Pililis Sotirios, Pliouta Loukia, Kountouri Aikaterini, Papanikolaou Ioannis S, Lambadiari Vaia, Ikonomidis Ignatios Journal of clinical medicine. 2025 Jan; 14(Jan):doi: 10.3390/jcm14020428. pii: 428.
Nenhuma revista foi definida para este congresso.